Modern Chinese Medicine Group Co., Ltd. has announced a second postponement in sending out its shareholder circular for the proposed major transaction involving the acquisition of sale shares.

The company had previously targeted 30 April 2026 for despatch, as disclosed in its 9 February 2026 delay announcement. Additional time is now required to finalise the pro-forma financial information of the enlarged group. As a result, management expects the circular to be distributed on or before 30 June 2026.

To accommodate the revised timeline, the company has applied to The Stock Exchange of Hong Kong Limited for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules. The stock exchange has not yet granted the waiver; the company will issue further updates when available.

The board currently comprises three executive directors—Sun Xinlei, Zhang Hongli and Jia Yanru—and three independent non-executive directors—Liu Ling, Leung Tsz Wing and Wong Chi Kin.

The announcement was authorised for release by executive director Zhang Hongli on 30 April 2026 in Hong Kong.